
Biosimilar Patent Dance: Why FDA Approval Does Not Mean Launch
Why a biosimilar can win FDA approval years before launch: the BPCIA patent dance, 12 year exclusivity, settlements and what Biocon’s Pebrilzo deal shows.
Get the industry's most important news delivered every morning. Trusted by professionals at Pfizer, Moderna, and Mayo Clinic.
Free forever. Unsubscribe anytime. No spam.
Want deeper analysis? Check out our premium tier.
Everything you need to stay ahead in biotech, delivered in 5 minutes every morning.
Key deals, clinical milestones, regulatory updates, and funding rounds. No fluff—just the signal you need to start your day informed.
Track emerging companies before they break out. We cover Series A/B rounds, preclinical breakthroughs, and founder movements others miss.
Enrollment trends, site activation updates, FDA decisions, and patient recruitment insights that impact your trials and investments.
Curated intelligence from a team with 15+ years of biotech journalism experience. We filter out the noise so you get only what matters. Free tier gives you everything you need to stay informed.
From bench scientists to C-suite executives, BioMed Nexus is the daily habit for biotech professionals.
Not all biotech newsletters are created equal. Here's how we compare.
Everything you need to know about the best biotech newsletter.
Join 95,000+ biotech professionals who trust BioMed Nexus for their daily industry intelligence.
Free forever. Unsubscribe anytime. No spam.
Want deeper analysis? Check out our premium tier.
Breakthroughs, pipelines, data drops, and deals shaping the biotech landscape.

Why a biosimilar can win FDA approval years before launch: the BPCIA patent dance, 12 year exclusivity, settlements and what Biocon’s Pebrilzo deal shows.

FDA approved AstraZeneca’s Klygefa, a weekly self injected C5 inhibitor for AChR positive myasthenia gravis. What PREVAIL showed and what is still unknown.

FDA issued a complete response letter for Summit’s ivonescimab in EGFR mutated lung cancer, disclosed Nov 15, 2026, citing no statistically significant OS gain.

Reuters reports FDA has shelved its national priority voucher pilot; HHS says it is ongoing. What 22 voucher holders and nine pending reviews face now.
BioMed Nexus delivers a fast, daily industry briefing for leaders across biotech, medtech, and pharma. Every weekday morning, we curate the most important developments, high-signal insights, and need-to-know updates so you can stay informed, move quickly, and make confident decisions in a rapidly evolving landscape.